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Systematic Screening of 
Chemokines to Identify Candidates 
to Model and Create Ectopic 
Lymph Node Structures for Cancer 
Immunotherapy
Yohsuke Yagawa1, Mark Robertson-Tessi2, Susan L. Zhou2, Alexander R. A. Anderson  2, 
James J. Mulé1,3 & Adam W. Mailloux1
The induction of ectopic lymph node structures (ELNs) holds great promise to augment immunotherapy 
against multiple cancers including metastatic melanoma, in which ELN formation has been associated 
with a unique immune-related gene expression signature composed of distinct chemokines. To 
investigate the therapeutic potential of ELNs induction, preclinical models of ELNs are needed for 
interrogation of these chemokines. Computational models provide a non-invasive, cost-effective 
method to investigate leukocyte trafficking in the tumor microenvironment, but parameterizing such 
models is difficult due to differing assay conditions and contexts among the literature. To better achieve 
this, we systematically performed microchemotaxis assays on purified immune subsets including 
human pan-T cells, CD4+ T cells, CD8+ T cells, B cells, and NK cells, with 49 recombinant chemokines 
using a singular technique, and standardized conditions resulting in a dataset representing 238 assays. 
We then outline a groundwork computational model that can simulate cellular migration in the tumor 
microenvironment in response to a chemoattractant gradient created from stromal, lymphoid, or 
antigen presenting cell interactions. The resulting model can then be parameterized with standardized 
data, such as the dataset presented here, and demonstrates how a computational approach can help 
elucidate developing ELNs and their impact on tumor progression.
Despite advances in immunotherapy and other treatment options, melanoma remains an increasing concern for 
caregivers, with over 60,000 new diagnoses of invasive melanoma per year in the United States1, and over 112,000 
cases projected per year by 20302. If detected early, surgical resection offers the best outcome and can often be 
curative. However, once the disease becomes metastatic, the prognostic outlook is bleak with only 16% of patients 
surviving 5 years3. For metastatic disease, immunotherapy can offer a handful of attractive options, which dis-
play potent but often incomplete clinical responses4–6. The use of cytokines and the more recent implementation 
of antibodies against immune checkpoint receptors CTLA-4 or PD-1 all display dramatic and durable clinical 
responses in a minority of patients7. Juxtaposed to this group of biologics is the adoptive transfer of autologous 
tumor-infiltrating lymphocytes (TIL) expanded ex vivo from patient tumors. TIL therapy was first pioneered at 
the NCI Surgery Branch8,9, and is now available at several institutions in the U.S. and abroad10–13. When combined 
with lympho-depleting, non-myeloablative chemotherapy prior to adoptive transfer, TIL therapy can display clin-
ical response rates approaching 50%14,15.
The initial presence of lymphocytes in the tumor microenvironment is presumptive to the success of any 
immunotherapy. The prognostic association of immune infiltrate in metastatic melanoma was at first contested, 
with some reports that TIL presence serves as an independent prognostic indicator16–18, and others reporting no 
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association with clinical outcome or lacking independence as a prognostic factor19–21. More detailed investiga-
tion suggests that taking into account the activation state or proliferation rate of TIL can better indicate positive 
prognosis22. Of importance, recent observations suggest that the presence of tumor-localized, ectopic lymph node 
structures (ELNs) is associated with better prognosis across a broad spectrum of tumor types including metastatic 
melanoma23, breast cancer24, colorectal carcinoma25, and non-small cell lung cancer26,27. ELNs are highly organ-
ized aggregates of leukocytes, often displaying distinct T cell and B cell zones, as well as, in some cases, clearly 
defined marginal zones with activated antigen presenting cells28. Structural features of ELNs, such as the de novo 
generation of lymphatic vessels, can greatly enhance the infiltration of TIL deeper into the tumor parenchyma29. 
Such dissemination away from the vasculature is highly associated with better clinical outcome30. While ELNs 
may be beneficial for the majority of cancer types, this is not universally true. The presence of ELNs serves as a 
negative prognostic indicator for a few cancer types such as hepatocellular carcinoma, and was associated with 
polarized immune cell subsets or suppressed immune response31 demonstrating a clear dichotomy based on 
different microenvironments. Taken together, the organization, activation state, and polarization of the microen-
vironment appear just as important as the number of TIL.
Looking forward, the ability to induce or construct ELNs with anti-tumor activity holds great promise to help 
recruit TIL to the tumor microenvironment and enhance their anti-tumor activity, particularly in solid tumors 
devoid of these structures. To help develop such a strategy requires the creation of sound preclinical models in 
which to study ELNs formation. The localization of lymphocytes is largely governed by networks of chemokines, 
which guide their trafficking to different parts of the body at different stages of development, maturation, and 
activation. In similar fashion to the trafficking in a conventional peripheral lymph node, lymphocyte involvement 
in ELNs likely depends on a network of chemokines produced by resident stroma or resident leukocytes such as 
dendritic cells. Indeed, our previous work identified a tumor gene expression signature associated with the pres-
ence of ELNs in certain human solid tumors that encodes for 12 distinct chemokines23–25,32.
We are interested in employing these chemokines as leads to construct or induce ELNs in the solid tumor 
microenvironment with the intent to potentially enhance immunotherapies, particularly in those devoid of such 
structures. To achieve this goal will first require a series of fundamental biologic studies and modeling. It is 
known that chemokines and their cognate receptors have been extensively studied, but differing methodologies 
and sources of responding cells have made comparing chemokine/chemokine receptor axes across publications 
difficult to interpret. A dataset reporting chemoattractive potential using a single methodology as well as a similar 
cell isolation technique, migration time, and chemokine concentration range would greatly enhance the param-
eterization of in silico ELNs models, and inform preclinical in vivo murine models investigating ELN formation 
and function. Here, we have used a conventional transwell migration assay to first catalogue the chemotactic 
index (CI) of 48 recombinant murine chemokines on resting pan T cells, CD4+ T cells, CD8+ T cells, B cells, and 
NK cells immunomagnetically isolated from normal C57BL/6 spleen, including the 12 chemokines associated 
with ELNs formation in humans. We also catalogue the CI for select chemokines for activated B cells and T cells. 
Using this database, the CI of different chemokines can be directly compared, and may serve as a valuable tool for 
the parameterization of preclinical animal models. In addition, we introduce a groundwork mathematical model 
able to make use of standardized chemoattraction data that can serve as a basic infrastructure for more complex 
models in the future. The model makes use of reticular fibroblast cells (RFC) as a stromal source of chemokine 
production28, antigen presenting cells as an activating source for RFC and chemokine production, and general-
ized T cell and B cell populations responding to chemokine gradients32,33.
Materials and Methods
Animals. Female C57BL/6 mice were purchased from Harlan Laboratories (Indianapolis, IN). Mice were bred 
and maintained at the Animal Maintenance Facility at the H. Lee Moffitt Cancer Center and Research Institute 
(Tampa, FL) for at least 1 week prior to use, and were age-matched at 8 weeks or older before their usage in 
experiments. All mice were handled and treated in accordance with the institutional guidelines established by 
the animal review board for animal care at the H. Lee Moffitt Cancer Center and all experimental protocols were 
approved by the Institutional Animal Care and Use Committee (IACUC) at the University of South Florida.
Culture Medium. Complete medium (CM) consisted of RPMI 1640 medium with 10% heat-inactivated 
fetal bovine serum, 1 μM sodium pyruvate, 0.1 mM nonessential amino acids, 2 mM fresh L-glutamine, 100 μg/
mL streptomycin, 100 U/mL penicillin, 50 μg/mL gentamicin, 0.5 µg/mL fungizone (all from Life Technologies, 
Rockville, MD), and 0.05 mM β-mercaptoethanol (Sigma-Aldrich, St. Louis, MO).
Chemokines. Recombinant murine CCL2, 3, 4, 5, 6, 7, 8, 9/10, 11, 12, 19, 20, 21, 22, 24, 27, 28, CXCL1, 2, 4, 
5, 9, 10, 11, 12 SDF1β, 13, 15, and 16 were purchased from PeproTech (Rocky Hill, NJ), and CCL17, 25, CXCL3, 
17, CX3CL1, XCL1 and Chemerin were obtained from R&D Systems (Minneapolis, MN). In some cases, murine 
chemokines were not available, and human chemokines were used due to their known cross-species activity. 
Human CCL16, 18, CXCL6 and 8 were purchased from PeproTech, XCL2 was from Life Technologies (Carlsbad, 
CA) and CCL1, 13, 14, 15, 23, 26, CXCL7 and 14 were provided by ChemoCentryx (Mountain View, CA).
Isolation of Lymphocyte Populations. Spleens and the superficial inguinal, axillary, lateral axillary, mes-
enteric and cervical lymph nodes of mice were removed under sterile conditions and mechanically dissociated 
to prepare single-cell suspension with a 100-µm nylon mesh. Erythrocytes were lysed with RBC lysing buffer 
(0.15 M NH4Cl, 1 mM KHCO3, and 0.1 mM EDTA in sterile water). After incubation for 1 minute, cells were 
washed in 1x PBS and used for further experiments.
Pan T, CD4+ T, CD8+ T, B and NK cells were then isolated from splenocyte and lymph node cell suspensions 
using negative immunomagnetic isolation kits as per the manufacturer’s instructions: Pan T Cell isolation kit II, 
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CD4+ T Cell isolation kit II, CD8α+ T Cell isolation kit II, B Cell isolation kit and NK isolation kit for mouse 
(Miltenyi Biotech, Auburn, CA). Isolations were performed using a magnetic cell sorter (autoMACS) (Miltenyi 
Biotech, Auburn, CA). Pan T and B cell isolation enrichments were greater than 95%, CD4+ T and CD8+ T cells 
were greater than 90% and NK cells were greater than 80% as determined by flow cytometric analysis. See sup-
plemental Fig. 1.
Flow Cytometry. Cells were washed with flow buffer (0.01% NaN3, 2% FBS in PBS) and Fcγ III/II recep-
tor blocking was performed for B and NK cells by purified anti-mouse CD16/32 Fc blocking antibody (BD 
Biosciences, San Diego, CA). After incubation at 4 °C for 5 minutes, appropriate antibodies (1 µg/1 × 106 cells) 
for each cell marker were added to each sample and placed at 4 °C for 30 minutes. After washing with flow buffer, 
cells were fixed with 1% paraformaldehyde. Data acquisition was performed on FACSCalibur (Becton Dickinson, 
Mountain View, CA) and data analysis was done using FlowJo (Treestar, Ashland, OR). CD3+ CD19−, CD3+ 
CD4+, CD3+ CD8+, CD19+ CD3− and NK1.1+ CD3− cells were measured for Pan T, CD4+ T, CD8+ T, B and NK 
cell, respectively (all antibodies and isotype controls from BD Biosciences). For staining chemokine receptors, 
cells were incubated with anti-CCR7, -CXCR4 (BD Biosciences) or -CXCR5 antibodies (eBiosciences, San Diego, 
CA) for 40 minutes at room temperature.
Microchemotaxis Assay. Each chemokine was added to the lower chamber of a 24-well transwell (Costar, 
Cambridge, MA) at indicated concentrations in 600 μL of CM, and incubated at 37 °C in a humidified incubator 
with 5% CO2 for 30 minutes. Respective lymphocyte populations were resuspended at 1 × 107 cells/mL in CM, 
and 100 μL (1.0 × 106 cells) were seeded into 6.5-mm 24-well transwell inserts (Costar, Cambridge, MA), and 
allowed to incubate at 37 °C for 10 minutes. After pre-incubations, the upper chambers were moved into lower 
wells to start assay. To determine the actual input amount, 100 μL of cell suspension was added to 500 μL of CM 
and put into the lower wells directly and incubated without upper chambers. After 3 hour incubation at 37 °C, 
the upper chambers were removed and the migrating cells were retrieved. Cells were stained with the appropriate 
antibodies and added 2 × 105 polystyrene beads (Bangs Laboratories, Fishers, IN). Twenty thousand beads were 
then counted flow cytometrically. Baseline chemokinesis was determined by the fraction of cells moving into the 
lower chamber in control wells containing no chemotactic agent, and is expressed as a percent of seeded cells. 
The chemotactic index (CI) is calculated as the fraction of cells migrating in response to the chemotactic agent 
normalized to the chemokinesis background such that CI = (fraction of cells migrating to condition)/(fraction 
of cells migrating to control media). Transwell migration through 3 μm, 5 μm, and 8 μm pore sizes was compared 
(Supplemental Fig. 2), and the 5 μm pore size was selected for use. Data reported are representative of at least two 
experiments.
Activation Assay. Prior to CD4+ and CD8+ T cell activation, the culture plate was coated with 5 μg/mL of 
anti-CD3 and 1 μg/mL of anti-CD28 antibodies (BD Biosciences). T cells were resuspended to 1 × 106 cells/mL 
in CM and cultured at 37 °C for 5 days in the presence of 60 IU/mL of IL-2 (Prometheus, San Diego, CA). For B 
cell activation, B cells were resuspended in RPMI 1640/1% FBS containing 10 μg/mL LPS (Sigma-Aldrich) and 
cultured for 3 days. Analysis was performed on CD4+CD25+, CD8+CD25+ and CD19+CD69+ cells for activated 
CD4+ T, CD8+ T and B cells, respectively (Supplemental Fig. 3A–C).
Enzyme-linked Immunosorbent Assay (ELISA). ELISA was carried out to evaluate T and B cell activa-
tion (Supplemental Fig. 3D). After supernatants were harvested at day 5 in the T cell activation assay or at day 3 in 
the B cell activation assay, IFNγ and IgM were measured, respectively. Mouse IFNγ ELISA Kit II (BD Biosciences) 
Figure 1. Resting NK cells display higher chemokinesis than other lymphocyte populations. Chemokinesis is 
reported as the baseline random migration into the lower chamber of a control transwell assay containing no 
chemoattractants. ****p < 0.0001.
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and Mouse IgG ELISA Quantitation Set (Bethyl laboratories, Montgomery, TX) were used in this experiment 
according to the manufacturer’s instructions.
Statistical Analysis. Unpaired student t-test was performed for each chemokine concentration versus con-
trol wells containing no chemokine using GraphPad Prism 5.04 software (GraphPad Software, La Jolla, CA). 
Microchemotaxis assays were performed on individually isolated/activated wells for each cell population (n = 4).
Mathematical Model. A cellular automaton model was developed to investigate the effect of ELNs on the 
organization and effectiveness of the immune response to a nearby tumor. The mathematical model is simulated 
in two dimensions and contains a tumor, a patch of fixed RFC, and four types of motile cells that move in a con-
tinuous domain (i.e., off-lattice): inactive T cells, activated T cells, resting antigen presenting cells (APCOFF), and 
activated marginal zone antigen presenting cells (APCM). The tumor is represented by a circle of radius R, where 
Figure 2. Resting T cell chemoattraction. (A) Pan T cell CI in response to CCL19, CCL21, CXCL10, and 
CXCL11 at the indicated concentration ranges. (B) Resting enriched CD4+ T cell response to CCL19, CCL21, 
and CXCL10 at the indicated concentration ranges. (C) Resting enriched CD8+ T cell response to CCL19, 
CCL21, CXCL10, and CXCL11 at the indicated concentration ranges. *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001.
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we assume that the radius grows linearly in time in the absence of any immune response, and that the T-cell 
response causes a reduction in growth rate proportional to the number of tumor-infiltrating lymphocytes (L). The 
equation for tumor growth per time step of the simulation is given by:
R R g kL t( ) (1)t t1 = + − ∆+
where g is the innate tumor growth rate, k is the killing rate of TILs, and Δt is the time step used in the simulation. 
Assuming a disease state in which anti-tumor cytotoxicity can occur, increasing numbers of TILs would slow the 
growth and potentially cause the tumor to regress if kL > g.
APCOFF are introduced into the tumor area at a constant rate. The new cells are randomly positioned in an 
annulus centered around the tumor, with inner radius of (R − 500 µm) and outer radius of (R + 1500 µm). Once 
in the environment, they move with a combination of an unbiased random walk and a directed walk towards 
the tumor center, following tumor-produced inflammatory chemokine gradients. When an APCOFF is inside the 
tumor, the antigen collection process is simulated by converting the cell to an APCM, which can present anti-
gen to the T cells. These APCM are also motile, using an unbiased random walk in combination with a directed 
walk away from the tumor center, to represent the seeking of T cells and/or vasculature for subsequent antigen 
presentation.
Inactive T cells are added to the simulation with a constant rate, using the same annulus as for APCOFF cells. 
These cells have an unbiased random walk. When an inactive T cell encounters an APCM (based on the two cells 
being in proximity to each other at a given time step), the APCM activates the T cell. The APCM can activate a 
number of T cells before it is removed from the simulation. Active T cells follow a biased random walk in the 
direction of the tumor. When they cross the tumor boundary as determined by R, they become TIL, which affects 
the tumor killing rate as shown in Eq. 1. They remain TIL for a set period of time, after which they are removed 
from the simulation, as expired T cells have no further effect on the results.
To model the effect of ELNs, we randomly place a fixed number of RFC in a circular patch situated away from 
the tumor. Each RFC begins in the “off state” with no secretion of chemokines, and therefore no influence on 
the movement of any of the APC or T cells. However, when an APCM migrates and comes into “contact” with an 
RFC (based on the two cells’ proximity to each other), it will activate the RFC, which will in turn start to produce 
a chemokine gradient. For simplicity here, we model the chemokine gradient produced by an activated RFC as 
a two-dimensional Gaussian function centered at the cell. The total chemokine gradient for multiple activated 
RFCs is the sum of these Gaussians. As more RFC are activated, the chemokine signal becomes stronger. This 
gradient affects two of the motile cells, APCM and inactive T cells. For both of these cell types, when they detect 
the presence of chemokine gradient produced by RFC, movement is biased toward the ELNs patch. The bias scales 
with the strength of the gradient. We vary the number of RFC in different simulations to investigate this effect.
The random walks in the model were implemented as follows: the motile cells in the simulation are off-lattice 
and therefore can take any value for their position. The maximum travel distance for a cell in a time step is its 
kinetic speed multiplied by the time step. The algorithm selects a random distance between 0 and this maximal 
distance, and moves the cell in the direction of a randomly chosen angle. When there is an additional chemotactic 
term, a second random distance is chosen based on the maximum tactic speed, but the angle is fixed, directed 
towards the chemokine source (ascending the gradient). In this model, we do not consider spatial occupancy, so 
cells can get arbitrarily close to each other.
Name Value Units Reference
Growth rate of Tumor (g) 0.2 μm/min 41
Tumor death rate due to TIL (k) 0.0015 μm/min/cell 42
Kinetic speed of APCOFF 12 μm/min 43
Chemotactic speed of APCOFF 4 μm/min 43
Kinetic speed of APCM 20 μm/min 43
Chemotactic speed of APCM 10 μm/min 43
Kinetic speed of T cells 10 μm/min 44,45
Chemotactic speed of T cells 100 μm/min 44,45
Rate of adding new APCOFF to simulation 0.84 per min model specific
Rate of adding new inactive T cells to simulation 0.1 per min model specific
Lifespan of a TIL before expiration 1 day model specific
Max distance between two cells for activation to occur 15 μm model specific
Initial Conditions:
 Initial radius of the Tumor 200 μm model specific
 Radius of the ELN patch 750 μm model specific
 Distance from tumor to ELNs patch 2000 μm model specific
 Initial T-cell number 30 cells model specific
 Initial APCOFF number 10 cells model specific
Table 1. Parameters and initial conditions for the mathematical model.
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Chemokine (ng/ml) Pan T cell CD4+ T cell CD8+ T cell B cell NK cell
CCL1
0 1 ± 0.38 1 ± 0.47 1 ± 0.32 1 ± 0.39 1 ± 0.23
10 1.02 ± 0.24 1.09 ± 0.17 0.77 ± 0.16 0.94 ± 0.19 1.01 ± 0.24
100 0.77 ± 0.23 0.78 ± 0.26 0.78 ± 0.25 0.62 ± 0.27 1.01 ± 0.4
1,000 1.17 ± 0.42 1.28 ± 0.56 0.89 ± 0.29 1.01 ± 0.45 0.92 ± 0.29
CCL2
0 1 ± 0.09 1 ± 0.54 1 ± 0.27 1 ± 0.47 1 ± 0.03
10 0.96 ± 0.14 1.6 ± 1 1.03 ± 0.3 0.63 ± 0.32 3.78 ± 0.22***
100 1.2 ± 0.38 0.9 ± 0.4 0.99 ± 0.42 1.24 ± 1.12 3.23 ± 0.25**
1,000 1 ± 0.09 1.04 ± 0.53 0.97 ± 0.29 0.72 ± 0.54 1.77 ± 0.08**
CCL3
0 1 ± 0.25 1 ± 0.27 1 ± 0.24 1 ± 0.23 1 ± 0.14
10 0.77 ± 0.17 0.77 ± 0.23 0.75 ± 0.19 0.66 ± 0.21 1.34 ± 0.11
100 0.86 ± 0.11 0.8 ± 0.11 0.78 ± 0.09 0.68 ± 0.06 1.79 ± 0.25**
1,000 0.85 ± 0.08 0.86 ± 0.08 0.78 ± 0.05 0.89 ± 0.15 1.38 ± 0.07*
CCL4
0 1 ± 0.23 1 ± 0.29 1 ± 0.33 1 ± 0.26 1 ± 0.09
10 1.26 ± 0.11 1.33 ± 0.08 1.15 ± 0.07 1.37 ± 0.07 1.35 ± 0.03**
100 1.3 ± 0.1 1.33 ± 0.12 1.33 ± 0.22 0.75 ± 0.09 1.75 ± 0.11***
1,000 1.13 ± 0.11 1.24 ± 0.15 1.08 ± 0.03 0.9 ± 0.12 1.42 ± 0.3
CCL5
0 1 ± 0.23 1 ± 0.29 1 ± 0.33 1 ± 0.26 1 ± 0.09
10 1.25 ± 0.09 1.26 ± 0.16 1.23 ± 0.15 0.91 ± 0.27 1.37 ± 0.03**
100 1.15 ± 0.08 1.05 ± 0.12 1.3 ± 0.11 0.76 ± 0.13 1.62 ± 0.1**
1,000 1.22 ± 0.14 1.25 ± 0.17 1.1 ± 0.16 0.93 ± 0.16 1.52 ± 0.11**
CCL6
0 1 ± 0.08 1 ± 0.09 1 ± 0.06 1 ± 0.17 1 ± 0.26
10 0.91 ± 0.08 0.97 ± 0.14 0.84 ± 0.27 1.82 ± 0.21 0.82 ± 0.17
100 0.87 ± 0.08 0.73 ± 0.07 0.97 ± 0.06 1.56 ± 0.09 0.91 ± 0.17
1,000 1.01 ± 0.24 0.96 ± 0.36 1.12 ± 0.24 1.29 ± 0.18 1 ± 0.18
CCL7
0 1 ± 0.57 1 ± 0.69 1 ± 0.55 1 ± 0.56 1 ± 0.14
10 0.7 ± 0.34 0.65 ± 0.29 0.81 ± 0.49 0.4 ± 0.04 1.36 ± 0.1
100 0.94 ± 0.56 0.82 ± 0.52 2.51 ± 1.89 0.5 ± 0.06 1.76 ± 0.16*
1,000 1.35 ± 0.85 0.73 ± 0.36 1.54 ± 1.12 0.67 ± 0.17 1.94 ± 0.05*
CCL8
0 1 ± 0.23 1 ± 0.29 1 ± 0.33 1 ± 0.26 1 ± 0.09
10 0.96 ± 0.08 1.02 ± 0.15 0.89 ± 0.07 1.26 ± 0.35 0.97 ± 0.11
100 0.8 ± 0.01 0.79 ± 0.05 0.74 ± 0.09 0.72 ± 0.03 0.97 ± 0.07
1,000 1.1 ± 0.17 1.06 ± 0.21 1.07 ± 0.25 1.36 ± 0.63 1.05 ± 0.12
CCL9
0 1 ± 0.08 1 ± 0.09 1 ± 0.06 1 ± 0.17 1 ± 0.26
10 0.91 ± 0.07 0.77 ± 0.11 3.76 ± 1.77 1.96 ± 0.62 1.05 ± 0.13
100 0.86 ± 0.13 0.71 ± 0.18 0.99 ± 0.36 1.96 ± 0.62 0.93 ± 0.18
1,000 1.14 ± 0.22 1.21 ± 0.57 1.25 ± 0.63 2.18 ± 0.59* 0.99 ± 0.05
CCL11
0 1 ± 0.08 1 ± 0.09 1 ± 0.06 1 ± 0.17 1 ± 0.26
10 0.75 ± 0.03 0.77 ± 0.27 0.99 ± 0.35 1.05 ± 0.09 0.88 ± 0.15
100 0.75 ± 0.15 0.74 ± 0.2 0.89 ± 0.29 1.05 ± 0.09 0.82 ± 0.19
1,000 1.09 ± 0.4 1.16 ± 0.46 1.29 ± 0.52 2.51 ± 0.56* 1.35 ± 0.4
CCL12
0 1 ± 0.08 1 ± 0.09 1 ± 0.06 1 ± 0.17 1 ± 0.26
10 0.8 ± 0.06 0.9 ± 0.1 1.06 ± 0.37 2.01 ± 0.2** 0.97 ± 0.22
100 0.94 ± 0.08 0.99 ± 0.12 1.06 ± 0.37 1.62 ± 0.51 1.51 ± 0.42
1,000 1.21 ± 0.44 1.26 ± 0.36 1.46 ± 0.67 1.96 ± 0.64 2.54 ± 0.34*
CCL13
0 1 ± 0.08 1 ± 0.07 1 ± 0.04 1 ± 0.18 1 ± 0.05
10 1.13 ± 0.08 1.09 ± 0.1 1.23 ± 0.02*** 0.94 ± 0.07 1.91 ± 0.07****
100 1.42 ± 0.11 1.3 ± 0.09* 1.72 ± 0.1*** 1.18 ± 0.1 2.01 ± 0.06****
1,000 2.05 ± 0.44 1.72 ± 0.39* 2.88 ± 0.46** 1.18 ± 0.14 1.96 ± 0****
CCL14
0 1 ± 0.08 1 ± 0.18 1 ± 0.04 1 ± 0.18 1 ± 0.05
10 1.13 ± 0.19 1.2 ± 0.12 0.91 ± 0.12 0.94 ± 0.07 0.92 ± 0.03
100 1.02 ± 0.27 0.87 ± 0.07 0.83 ± 0.18 1.18 ± 0.1 0.95 ± 0.1
1,000 1.16 ± 0 1.08 ± 0.1 1.08 ± 0.04 1.18 ± 0.14 1.37 ± 0.23
CCL15
0 1 ± 0.1 1 ± 0.11 1 ± 0.09 1 ± 0.13 1 ± 0.14
10 0.87 ± 0.04 0.83 ± 0.09 0.87 ± 0.07 0.71 ± 0.09 0.83 ± 0.08
100 0.89 ± 0.03 0.93 ± 0.07 0.87 ± 0.03 1.09 ± 0.27 1.01 ± 0.01
1,000 1 ± 0.07 1.04 ± 0.07 0.99 ± 0.17 0.86 ± 0.1 0.88 ± 0.06
Continued
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Chemokine (ng/ml) Pan T cell CD4+ T cell CD8+ T cell B cell NK cell
CCL16
0 1 ± 0.17 1 ± 0.15 1 ± 0.16 1 ± 0.18 1 ± 0.23
10 1.84 ± 0.21** 2.04 ± 0.41* 1.68 ± 0.12 1.42 ± 0.55 1.11 ± 0.22
100 1.48 ± 0.07** 1.53 ± 0.13** 1.42 ± 0.07 1.08 ± 0.06 0.98 ± 0.06
1,000 1.12 ± 0.05 1.21 ± 0.07 1.09 ± 0.05 0.97 ± 0.45 0.94 ± 0.1
CCL17
0 1 ± 0.38 1 ± 0.47 1 ± 0.32 1 ± 0.39 1 ± 0.23
10 0.83 ± 0.14 0.86 ± 0.21 0.64 ± 0.21 0.65 ± 0.06 0.91 ± 0.31
100 1.15 ± 0.36 1.33 ± 0.5 0.8 ± 0.21 0.5 ± 0.21 0.91 ± 0.31
1,000 0.98 ± 0.38 1.07 ± 0.44 0.74 ± 0.35 0.83 ± 0.32 0.84 ± 0.35
CCL18
0 1 ± 0.25 1 ± 0.27 1 ± 0.24 1 ± 0.23 1 ± 0.14
10 1.01 ± 0.22 1.1 ± 0.23 1.02 ± 0.24 0.42 ± 0.17 0.87 ± 0.32
100 1.01 ± 0.13 1.05 ± 0.1 0.97 ± 0.14 0.26 ± 0.06 0.88 ± 0.24
1,000 0.98 ± 0.06 1.06 ± 0.04 1 ± 0.09 0.36 ± 0.12 0.7 ± 0.04
CCL19
0 1 ± 0.33 1 ± 0.38 1 ± 0.34 1 ± 0.41 ND
10 5.26 ± 0.65** 9.02 ± 1.05*** 1.23 ± 0.19 1.89 ± 0.46 ND
100 14.19 ± 1.1**** 20.6 ± 1.56**** 8.69 ± 0.79*** 2.21 ± 0.19** ND
1,000 27.73 ± 3.11*** 28.3 ± 3.45*** 33.0 ± 3.28**** 2.43 ± 0.71* ND
CCL20
0 1 ± 0.08 1 ± 0.09 1 ± 0.06 1 ± 0.17 1 ± 0.26
10 1.22 ± 0.13 1.31 ± 0.19 1.36 ± 0.42 4.13 ± 0.88** 1.22 ± 0.23
100 1.13 ± 0.12 1.33 ± 0.18 0.91 ± 0.18 3.12 ± 0.76** 1.1 ± 0.22
1,000 1.1 ± 0.28 1.31 ± 0.55 1.06 ± 0.29 3.94 ± 0.66** 0.75 ± 0.16
CCL21
0 1 ± 0.33 1 ± 0.37 1 ± 0.34 1 ± 0.41 ND
10 1.4 ± 0.28 1.75 ± 0.4 0.96 ± 0.17 1.16 ± 0.12 ND
100 11.82 ± 1.8*** 21 ± 3.32*** 2.18 ± 0.25** 2.83 ± 0.63* ND
1,000 51.67 ± 5.66*** 71.8 ± 7.65**** 36.9 ± 4.38*** 4.03 ± 2.47 ND
CCL22
0 1 ± 0.57 1 ± 0.69 1 ± 0.55 1 ± 0.56 1 ± 0.09
10 1.4 ± 0.33 0.7 ± 0.28 0.93 ± 0.61 0.52 ± 0.12 1.06 ± 0.03
100 0.95 ± 0.38 0.86 ± 0.22 1.47 ± 1.3 0.62 ± 0.02 1.02 ± 0.01
1,000 1.44 ± 0.9 1.46 ± 0.71 1.66 ± 1.41 1.5 ± 0.99 1.05 ± 0.07
CCL23
0 1 ± 0.25 1 ± 0.27 1 ± 0.24 1 ± 0.23 1 ± 0.14
10 0.86 ± 0.2 0.85 ± 0.16 0.94 ± 0.24 0.47 ± 0.09 1.04 ± 0.02
100 0.63 ± 0.06 0.61 ± 0.07 0.65 ± 0.09 0.41 ± 0.18 0.9 ± 0.12
1,000 0.85 ± 0.09 0.87 ± 0.06 0.93 ± 0.14 0.32 ± 0.14 1.12 ± 0.06
CCL24
0 1 ± 0.57 1 ± 0.69 1 ± 0.55 1 ± 0.56 1 ± 0.09
10 0.92 ± 0.4 0.5 ± 0.17 1.01 ± 0.74 0.61 ± 0.26 1 ± 0.06
100 0.77 ± 0.46 0.46 ± 0.24 0.46 ± 0.26 0.33 ± 0 0.97 ± 0.02
1,000 0.55 ± 0.3 0.46 ± 0.19 0.45 ± 0.23 0.36 ± 0.06 0.89 ± 0.08
CCL25
0 1 ± 0.05 1 ± 0.13 1 ± 0.46 1 ± 0.26 1 ± 0.02
10 0.69 ± 0.15 0.7 ± 0.23 0.66 ± 0.3 0.58 ± 0.5 0.86 ± 0.06
100 0.58 ± 0.28 0.58 ± 0.26 1.03 ± 0.65 0.56 ± 0.44 0.64 ± 0.25
1,000 0.5 ± 0.35 0.68 ± 0.15 1.12 ± 0.91 0.76 ± 0.55 0.73 ± 0.18
CCL26
0 1 ± 0.1 1 ± 0.11 1 ± 0.09 1 ± 0.13 1 ± 0.14
10 0.47 ± 0.01 0.38 ± 0.04 0.62 ± 0.07 0.67 ± 0.14 0.99 ± 0.18
100 0.64 ± 0.1 0.46 ± 0.06 0.97 ± 0.36 0.99 ± 0.35 1.11 ± 0.23
1,000 0.59 ± 0.09 0.5 ± 0.11 0.84 ± 0.08 0.88 ± 0.11 0.94 ± 0.03
CCL27
0 1 ± 0.23 1 ± 0.29 1 ± 0.33 1 ± 0.26 1 ± 0.09
10 1.34 ± 0.22 1.14 ± 0.08 1.09 ± 0.08 2.03 ± 0.23 1.02 ± 0.07
100 1.09 ± 0.09 1.14 ± 0.08 0.91 ± 0.03 1.22 ± 0.04 0.92 ± 0.04
1,000 1.18 ± 0.07 1.41 ± 0.1 0.94 ± 0.03 2.28 ± 0.13* 0.93 ± 0.06
CCL28
0 1 ± 0.57 1 ± 0.69 1 ± 0.55 1 ± 0.56 1 ± 0.09
10 0.88 ± 0.68 0.71 ± 0.28 0.67 ± 0.5 0.39 ± 0.2 0.84 ± 0.02
100 0.62 ± 0.28 0.82 ± 0.29 0.8 ± 0.45 0.8 ± 0.33 0.98 ± 0.1
1,000 0.84 ± 0.39 0.74 ± 0.29 1.69 ± 1.2 1.11 ± 0.68 1.16 ± 0.1
CXCL1
0 1 ± 0.03 1 ± 0.1 1 ± 0.03 1 ± 0.45 1 ± 0.08
10 1.1 ± 0.08 1.08 ± 0.02 1.09 ± 0.25 1.04 ± 0.19 0.93 ± 0.16
100 1.02 ± 0.09 1.03 ± 0.1 0.94 ± 0.12 1.42 ± 0.24 0.91 ± 0.19
1,000 1.01 ± 0.22 0.93 ± 0.19 1.05 ± 0.19 1.23 ± 0.39 0.92 ± 0.2
Continued
www.nature.com/scientificreports/
8Scientific REPORTS | 7: 15996  | DOI:10.1038/s41598-017-15924-2
Chemokine (ng/ml) Pan T cell CD4+ T cell CD8+ T cell B cell NK cell
CXCL2
0 1 ± 0.03 1 ± 0.1 1 ± 0.03 1 ± 0.45 1 ± 0.08
10 0.97 ± 0.08 0.95 ± 0.08 0.99 ± 0.13 0.73 ± 0.07 0.95 ± 0.23
100 0.94 ± 0.07 0.92 ± 0.07 0.99 ± 0.25 1.02 ± 0.32 0.86 ± 0.18
1,000 1.03 ± 0.23 1.02 ± 0.25 0.99 ± 0.25 0.83 ± 0.37 0.96 ± 0.22
CXCL3
0 1 ± 0.05 1 ± 0.13 1 ± 0.46 1 ± 0.26 1 ± 0.02
10 0.36 ± 0.18 0.57 ± 0.1 0.72 ± 0.54 0.74 ± 0.67 0.92 ± 0.06
100 0.39 ± 0.29 0.53 ± 0.15 0.97 ± 0.66 1.1 ± 0.89 0.95 ± 0.06
1,000 0.66 ± 0.51 0.72 ± 0.24 1.05 ± 0.8 0.6 ± 0.51 0.89 ± 0.1
CXCL4
0 1 ± 0.11 1 ± 0.04 1 ± 0.26 1 ± 0.22 1 ± 0.14
10 0.76 ± 0.34 1.16 ± 0.75 0.53 ± 0.14 0.61 ± 0.33 0.79 ± 0.02
100 0.71 ± 0.22 1.01 ± 0.09 0.96 ± 0.06 0.38 ± 0.22 0.97 ± 0.11
1,000 1.51 ± 0.52 1.06 ± 0.54 1.87 ± 0.07* 0.73 ± 0.11 0.95 ± 0.09
CXCL5
0 1 ± 0.04 1 ± 0.08 1 ± 0.01 1 ± 0.17 1 ± 0.31
10 1.09 ± 0.12 1.56 ± 0.48 1.09 ± 0.17 2.45 ± 0.66 1.15 ± 0.22
100 1.11 ± 0.08 1.5 ± 0.24 1.44 ± 0.58 2.24 ± 0.31* 0.93 ± 0.21
1,000 1.32 ± 0.4 1.69 ± 0.73 0.95 ± 0.22 0.38 ± 0.06 1.39 ± 0.26
CXCL6
0 1 ± 0.1 1 ± 0.11 1 ± 0.09 1 ± 0.13 1 ± 0.14
10 0.53 ± 0.04 0.45 ± 0.06 0.61 ± 0.09 0.97 ± 0.32 0.85 ± 0.11
100 0.42 ± 0.02 0.36 ± 0.05 0.51 ± 0.13 0.67 ± 0.07 0.95 ± 0.06
1,000 0.55 ± 0.08 0.44 ± 0.11 0.67 ± 0.08 1.18 ± 0.39 0.96 ± 0.06
CXCL7
0 1 ± 0.05 1 ± 0.13 1 ± 0.46 1 ± 0.26 1 ± 0.02
10 0.76 ± 0.41 1 ± 0.49 0.57 ± 0.33 0.67 ± 0.46 0.84 ± 0.08
100 0.59 ± 0.37 0.68 ± 0.24 1.07 ± 0.85 0.76 ± 0.62 0.89 ± 0.08
1,000 1.05 ± 0.43 1.09 ± 0.03 0.78 ± 0.56 0.73 ± 0.63 0.98 ± 0.01
CXCL8
0 1 ± 0.1 1 ± 0.11 1 ± 0.09 1 ± 0.13 1 ± 0.14
10 0.5 ± 0.07 0.39 ± 0.05 0.59 ± 0.09 0.87 ± 0.17 0.87 ± 0.07
100 0.44 ± 0.01 0.32 ± 0.03 0.5 ± 0.03 0.69 ± 0.06 0.83 ± 0.09
1,000 0.52 ± 0.05 0.47 ± 0.05 0.58 ± 0.05 0.99 ± 0.13 0.9 ± 0.16
CXCL9
0 1 ± 0.17 1 ± 0.15 1 ± 0.16 1 ± 0.18 1 ± 0.23
10 0.84 ± 0.05 0.96 ± 0.05 0.73 ± 0.05 1.11 ± 0.26 0.9 ± 0.2
100 0.9 ± 0.07 0.95 ± 0.08 0.73 ± 0.05 0.63 ± 0.1 1.18 ± 0.17
1,000 3.25 ± 0.22*** 2.78 ± 0.43** 2.63 ± 0.01**** 1.02 ± 0.3 1.95 ± 0.2**
CXCL10
0 1 ± 0.17 1 ± 0.15 1 ± 0.16 1 ± 0.18 1 ± 0.23
10 4.47 ± 0.19**** 2.11 ± 0.19** 5.17 ± 0.16**** 1.1 ± 0.19 1.87 ± 0.1**
100 4.66 ± 0.63*** 2.12 ± 0.29** 5.37 ± 0.8*** 0.87 ± 0.05 1.7 ± 0.05**
1,000 4 ± 0.85** 2.1 ± 0.57* 4.21 ± 0.89** 0.84 ± 0.11 1.8 ± 0.18**
CXCL11
0 1 ± 0.44 1 ± 0.41 1 ± 0.5 1 ± 0.35 1 ± 0.25
10 1.89 ± 0.27* 1.27 ± 0.4 1.93 ± 0.27* 2.2 ± 0.5 1.9 ± 0.26*
100 6.34 ± 2.17* 3.02 ± 1.24 7.64 ± 2.48* 0.32 ± 0.45 3.2 ± 0.87*
1,000 1.97 ± 0.7 2.22 ± 0.8 1.76 ± 0.66 1.64 ± 1.03 1.69 ± 0.76
CXCL12
0 1 ± 0.33 1 ± 0.38 1 ± 0.34 1 ± 0.4 1 ± 0.1
10 2.6 ± 0.44** 2.83 ± 0.52** 2.14 ± 0.35* 3.2 ± 0.39** 1.84 ± 0.19**
100 6.92 ± 0.28**** 8.19 ± 0.34**** 5.34 ± 0.38*** 9.23 ± 0.85*** 3.23 ± 0.35***
1,000 7.13 ± 0.18**** 9.59 ± 0.19**** 4.44 ± 0.17**** 10.3 ± 0.51**** 3.11 ± 0.16***
CXCL13
0 1 ± 0.06 1 ± 0.02 1 ± 0.03 1 ± 0.04 1 ± 0.11
10 1.19 ± 0.11 1.36 ± 0.15* 1.32 ± 0.04*** 2 ± 0.41* 0.93 ± 0.03
100 1.1 ± 0.04 1.23 ± 0.08** 1.14 ± 0.04** 2.24 ± 0.32** 0.9 ± 0.1
1,000 1.7 ± 0.02**** 2.01 ± 0.04**** 2.07 ± 0.13*** 27.7 ± 0.47**** 1.16 ± 0.06
CXCL14
0 1 ± 0.05 1 ± 0.13 1 ± 0.46 1 ± 0.26 1 ± 0.02
10 0.53 ± 0.35 0.56 ± 0.18 0.94 ± 0.72 1.09 ± 0.95 1 ± 0.07
100 0.59 ± 0.34 0.6 ± 0.22 0.73 ± 0.57 1.08 ± 0.73 0.85 ± 0.08
1,000 0.83 ± 0.6 0.97 ± 0.53 0.92 ± 0.69 0.9 ± 0.55 0.94 ± 0.01
CXCL15
0 1 ± 0.03 1 ± 0.1 1 ± 0.03 1 ± 0.45 1 ± 0.08
10 0.66 ± 0.1 0.53 ± 0.1 0.8 ± 0.18 1.03 ± 0.19 1.13 ± 0.12
100 0.47 ± 0.07 0.34 ± 0.01 0.6 ± 0.12 1.03 ± 0.19 0.95 ± 0.14
1,000 0.63 ± 0.12 0.54 ± 0.12 0.75 ± 0.13 1.04 ± 0.33 1.03 ± 0.2
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To summarize the model, there are two chemokine gradients, one from the tumor and one from the RFCM. 
APCOFF and active T cells move towards the tumor, and APCM and inactive T cells move away from the tumor. 
When there are activated RFCM, APCM and inactive T cells are both drawn to the ELNs. The simulation is initial-
ized with a small tumor, a patch where RFCOFF cells are placed, and 30 APCOFF and inactive T cells. Parameters 
used in the model are shown in Table 1, with those labeled as ‘model specific’ refer to parameters that are highly 
variable in practice (e.g., tumor size, ELN-tumor distance, influx rate of immune cells); values were chosen that 
were in line with biologically reasonable ranges.
Results
Resting pan T cells, B cells, CD4+ T cells, CD8+ T cells, or NK cells were immunomagnetically isolated and 
chemotaxis assays were performed for the 48 chemokines listed in Table 2 at three different concentrations: 10 ng/
mL, 100 ng/mL, and 1,000 ng/mL. Non-directional random motility, or chemokinesis, was assessed for each cell 
population using control wells containing no chemokine gradient. Resting pan T cells, CD4+ T cells, CD8+ T 
cells, and B cells all displayed relativity low levels of chemokinesis while NK cells displayed significantly higher 
non-directional movement (Fig. 1). Directional movement in response to a chemokine concentration gradient 
was normalized to baseline chemokinesis for each respective cell type, and is reported as a chemotactic index 
(CI) for each condition. CI was calculated as the fraction of cells that migrated into the lower chamber from the 
total number of cells seeded in the top chamber for each condition, and then divided by the fraction of cells that 
migrated into the lower chamber randomly in control wells (i.e. by chemokinesis).
Resting pan T cells displayed significant and concentration dependent chemoattraction toward CCL19 
and CCL21, and to a lesser extent CXCL10 and CXCL12. Statistically significant CI was also observed toward 
CCL16, CXCL9, CXCL11, CXCL13, and CXCL16 at some concentrations, but was of low magnitude or was not 
concentration-dependent. Resting CD4+ and CD8+ T cells displayed similar concentration-dependent chemoat-
traction toward CCL19, CCL21, CXCL10, and CXCL12 as pan T cells, and displayed variable low magnitude 
CI toward CCL13, CCL16, CXCL9, CXCL11, CXCL13, and/or CXCL16 (Fig. 2 and Table 2). Significant and 
concentration-dependent chemoattraction of resting B cells was restricted to CXCL12 and CXCL13, with low 
magnitude statistically significant CI observed toward some concentrations of CCL9, CCL11, CCL12, CCL19, 
CCL20, CCL21, CCL27, CXCL5, and XCL2 (Fig. 3 and Table 2). Resting NK cells displayed statistically signifi-
cant and concentration-dependent chemoattraction toward a broad range of chemokines including CCL2, CCL3, 
CCL4, CCL5, CCL7, CCL12, CCL13, CXCL9, CXCL10, CXCL11, and CXCL12 (Fig. 4 and Table 2). However, NK 
cells did not display CI values greater than 4 toward any chemokine at any concentration, perhaps reflecting the 
high baseline chemokinesis displayed by resting NK cells (Fig. 1).
Chemokine (ng/ml) Pan T cell CD4+ T cell CD8+ T cell B cell NK cell
CXCL16
0 1 ± 0.11 1 ± 0.04 1 ± 0.26 1 ± 0.22 1 ± 0.14
10 1.34 ± 0.91 0.77 ± 0.37 1.06 ± 0.67 0.84 ± 0.55 0.77 ± 0
100 1.19 ± 0.7 1.04 ± 0.12 1.1 ± 0.08 0.62 ± 0.46 0.96 ± 0.1
1,000 1.96 ± 0.07** 0.84 ± 0.31 1.87 ± 0.06* 1.1 ± 0.26 0.92 ± 0.05
CXCL17
0 1 ± 0.38 1 ± 0.47 1 ± 0.32 1 ± 0.39 1 ± 0.23
10 0.86 ± 0.16 0.84 ± 0.21 0.7 ± 0.16 0.64 ± 0.12 0.98 ± 0.23
100 0.69 ± 0.19 1.23 ± 0.54 0.67 ± 0.26 0.41 ± 0.12 0.91 ± 0.28
1,000 1.09 ± 0.41 1.23 ± 0.54 0.77 ± 0.31 0.92 ± 0.4 1.11 ± 0.38
CX3CL1
0 1 ± 0.38 1 ± 0.47 1 ± 0.32 1 ± 0.39 1 ± 0.23
10 0.9 ± 0.16 0.83 ± 0.17 0.87 ± 0.21 1.01 ± 0.09 1.06 ± 0.14
100 0.73 ± 0.15 0.61 ± 0.13 0.66 ± 0.21 0.72 ± 0.19 0.91 ± 0.28
1,000 0.99 ± 0.37 0.94 ± 0.41 0.87 ± 0.3 0.94 ± 0.26 1.05 ± 0.32
XCL1
0 1 ± 0.05 1 ± 0.13 1 ± 0.46 1 ± 0.26 1 ± 0.04
10 0.61 ± 0.36 0.57 ± 0.16 0.85 ± 0.64 0.79 ± 0.67 0.7 ± 0.24
100 0.52 ± 0.29 0.47 ± 0.23 0.76 ± 0.55 0.76 ± 0.69 1.04 ± 0.1
1,000 0.74 ± 0.58 0.62 ± 0.05 1.09 ± 0.77 0.9 ± 0.81 0.92 ± 0.16
XCL2
0 1 ± 0.17 1 ± 0.18 1 ± 0.25 1 ± 0.5 1 ± 0.05
10 1.62 ± 0.31 1.58 ± 0.27 1.72 ± 0.42 2.83 ± 0.19* 1.04 ± 0.11
100 1.33 ± 0.22 1.25 ± 0.17 1.58 ± 0.39 1.61 ± 0.01 0.84 ± 0.06
1,000 1.57 ± 0.01 1.52 ± 0.03 1.74 ± 0.07 2.12 ± 0.4 1.07 ± 0.12
Chemerin
0 1 ± 0.17 1 ± 0.15 1 ± 0.16 1 ± 0.18 0.67 ± 0.47
10 1.31 ± 0.21 1.22 ± 0.19 1.39 ± 0.23 0.69 ± 0.15 1.42 ± 1.02
100 1.1 ± 0.21 1.12 ± 0.22 1.07 ± 0.22 0.66 ± 0.06 0.77 ± 0.55
1,000 1.3 ± 0.33 1.38 ± 0.34 1.3 ± 0.39 0.82 ± 0.35 0.67 ± 0.49
Table 2. Chemotactic Index (CI) of Chemokines on lymphocyte Populations. Asterisks indicate a significant 
difference versus control (0ng/ml) per respective chemokine by unpaired t test: *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001.
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When activated, lymphocytes become more motile and often down-regulate expression of chemokine recep-
tors recognizing secondary lymphoid tissue-homing chemokines such as CCR7. This aids in emigration from the 
follicle and secondary lymphoid tissues34. Here, activation of pan T cells, enriched CD4+ T cells, and enriched 
CD8+ T cells with plate-bound anti-CD3 resulted in significantly increased chemokinesis. Similarly, but to a 
lesser extent, activation of B cells with LPS significantly increased chemokinesis (Fig. 5A). Despite higher baseline 
motility, activated T cells loose chemoattraction to lymphoid-homing chemokines as demonstrated by reduced CI 
toward CCL19 and CCL21 for pan T cell populations (Fig. 5B,C), and reduced chemoattraction of enriched CD4+ 
and CD8+ T cells toward CCL21 (Fig. 5D,E). In contrast, B cells displayed significantly increased chemoattraction 
toward CCL21 and CXCL13 upon activation with LPS (Fig. 5F,G). This likely reflects the divergent roles of B cells 
and T cells following activation in secondary lymphoid tissues with T cells often emigrating T-cell zones and 
recirculating into the periphery and with B cells clustering in follicles.
The standardized set of chemotaxis assays presented here demonstrate that chemokines differentially affect 
random and directed motion of lymphocytes. To investigate the implications of this regarding immune response 
and subsequent tumor growth depending on the presence of the ELNs we developed a phenomenological math-
ematical model of the tumor and surrounding environment that is able to make use of chemoattraction data an 
simulate different scenarios.
Figure 6 shows snapshots of the model at 14 days of simulation, under three different conditions for the RFC: 
(a) no RFC, (b) 5 RFC, and (c) 30 RFC. Time course plots for these and several other simulations with different 
RFC counts are shown in Fig. 7, in the left panel. The results suggest that the presence of the RFC has an impact 
on the immune response to the tumor, both in terms of T-cell activation and tumor reduction. In all cases, the 
tumor grows for an initial period since the immune system starts in an inactive state. Eventually, APCs present 
tumor antigens to inactive T cells, causing activation, migration, and accumulation of TILs inside the tumor and 
eventual tumor regression. The presence of higher numbers of RFC causes a faster immune response to occur: 
without an ELNs, the peak tumor size occurs at day 9; while for simulations with 100 RFC the peak tumor size 
is around 4 days, suggesting that the migratory organization of lymphocytes provided by the ELNs significantly 
accelerates the anti-tumor immune response. In the case with 100 RFC, the tumor also reaches a maximum size 
that is about 25% smaller than the simulation with no RFC. This advantage persists as tumor growth continues 
to decline. The right panel of Fig. 7 compares tumor sizes after 30 days of simulation. Of interest, having a small 
number of RFC cells (5–10) does not produce an immune response as effective as the case with no RFC or a high 
number of RFC. This nonlinear result is because the weak chemokine signal of the ELNs draws some nearby cells 
away from the tumor, but a lack of immune cell density limits the effectiveness of rapid activation. In essence, 
there is a need for critical mass in the ELNs to achieve efficient cell attraction and activation. This can be seen in 
Fig. 6B, where the dendritic cells are accumulated in the ELNs area, but inactive T cells remain predominantly in 
the tumor microenvironment due to the weak signaling from the ELNs patch.
Figure 3. Resting B cell chemoattraction. B cell CI in response to CXCL12 and CXCL13 at the indicated 
concentration ranges.
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Discussion
We had earlier identified a unique tumor-derived, 12-chemokine gene expression signature that could accurately 
predict the degree and type of lymphoid infiltrate, organized remarkably as ELNs that comprise - by immuno-
histochemistry staining - prominent B cell follicles, T cell marginal zones comprised of both CD4+ and CD8+ 
cell subsets, and associated follicular dendritic cells23. Of importance, there was a highly significant and consist-
ent association between a marked increase in overall patient survival, the value of the mean score of this gene 
expression signature, and the presence of ELNs in stage IV (non-locoregional) melanoma, colorectal cancer, and 
stage IV bladder cancer. However, we found that the majority of human solid tumors lacked the presence of these 
particular ELNs, and patients harboring these ‘poorly-immunogenic’ tumors have had uniformly poor prognosis 
(i.e. reduced overall survival). Thus, there is a clear unmet medical need to ‘reverse’ this tumor microenvironment 
(that lacks these particular ELNs) by manufacturing de novo ‘designer’ ELNs.
Lymphocyte recruitment to the tumor microenvironment represents an attractive target to enhance 
anti-tumor immunity. As we continue to study lymphocyte trafficking, it is increasingly necessary to view 
chemokine-mediated trafficking as networks of chemokines and chemokine receptors working in concert as 
Figure 4. NK cell chemoattraction. NK cell CI In response to CCL2, CCL3, CCL4, CCL5, CCL7, CCL12, 
CCL13, CXCL9, CXCL10, CXCL11, and CXCL12 at the indicated concentration ranges.
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opposed to individual chemoattractive axes. Understanding how chemokine receptor expression and lympho-
cyte responsiveness changes during the course of maturation, activation, and effector response will greatly inform 
the development of preclinical animal and mathematical models. The chemokine database described herein may 
serve as a normalized resource to parameterize such models.
Figure 5. Lymphocyte Activation increases chemokinesis and changes chemotactic response. (A) T 
cell populations activated with plate-bound anti-CD3 and B cells activated with LPS display increased 
chemokinesis. (B) CI of resting or activated pan T cells in response to CCL19. (C) CI of resting or activated pan 
T cells in response to CCL21. (D) CI of resting or activated enriched CD4+ T cells in response to CCL21. (E) 
CI of resting or activated enriched CD8+ T cells in response to CCL21. (F) CI of resting or activated B cells in 
response to CCL21. (G) CI of resting or activated B cells in response to CXCL13.
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Given a direct link between gene expression of certain chemokines within human solid tumor microenviron-
ments, the presence of tumor-localized ELNs, and addressing a clinical unmet need, we embarked on developing 
a standardized database of chemoattractive potentials of immune cell subsets for a broad range of chemokines 
to identify candidates for future engineering of ELNs. To approach this goal, we developed a strategy that com-
bined the use of defined, recombinant chemokines, highly enriched resting and activated immune cell subsets, 
with standardized microchemotaxis assays to provide potential leads to further test in mathematical models. In 
this regard, we are developing both mathematical and pre-clinical animal models of ELNs formation in which 
multiple elements are being interrogated. The inclusion of lymph node-derived primary cellular components, 
which normally provide chemotactic and homeostatic queues in conventional lymph nodes, are being genetically 
modified to express selected chemotactic (e.g., see Table 3) and lymphoid neogenesis-related genes to enhance 
ELN formation. These modified cell lines are being combined with tumor antigen-pulsed dendritic cells and 
then incorporated in biocompatible scaffold materials and administered to tumor-bearing mice as injectable 
or implantable matrices35. These matrices may provide two potential benefits when delivered to tumor-bearing 
hosts. First, they may serve as model systems to better understand the factors governing the formation and/or 
maintenance of ELNs with anti-tumor reactivity. Second, these matrix-based systems may function as a thera-
peutic platform by delivering, stimulating and expanding transplanted lymphocytes and/or dendritic cells. In 
addition, the inert nature of bio-scaffolds also allows for the implementation of microparticle or nanoparticle 
constructs for controlled release of soluble factors. Such measures can provide sustained environmental queues 
to augment antigen-presenting cell or lymphocyte longevity, maturation, and activation. The initial mathematical 
modeling presented herein will be further developed to include these parameters.
In regard to translating in vitro migration assays to in silico models, care must be taken to differentiate 
between non-directional movement known as chemokinesis and directional chemotaxis toward a chemokine 
gradient. CI, as it is calculated here, normalizes transwell migration relative to baseline chemokinesis. This 
denominator is greatly increased after lymphocyte activation. Without normalizing to baseline movement, the 
percentage of cells migrating may appear very high when the majority of migration can be accounted for by 
Figure 6. Snapshots of the mathematical model on day 14 of the simulation. (A) No RFC cells in the 
simulation. Tumor is in yellow. APCOFF (red circles), APCM (blue circles), inactive T cells (black ‘x’) and 
activated T cells (green ‘ + ’) are shown. (B) 5 RFC cells (red stars). Normalized chemokine gradient shown in 
gray. (C) 30 RFC cells.
Figure 7. Left: Tumor dynamics for different numbers of RFC (from 0 to 100) in the simulation. All plots are 
the average of 5 runs. Right: Tumor size at 30 days for each simulation.
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random motility. Because this database was constructed using a single methodology, time point, and concen-
tration range, CI can be compared across chemokines. For example, CCL19 and CCL21 are both well studied 
T cell chemoattractants; however, here CCL21 appears to be a 50% stronger chemoattractant compared to 
an equimolar amount of CCL19. In addition, this database serves to point out suboptimal chemoattractants 
whose combined cumulative effects may play an important role for in silico models such as the broad respon-
siveness observed for NK cells.
As a first step toward integrating this type of chemotactic data into an in silico model of ELNs formation, 
we developed a simple phenomenological mathematical model that predicts the chemokine gradient created 
as a result of lymphocyte, APC, and stromal interactions in the tumor microenvironment. Here, we consider 
secretion of a general chemoattractant for responding lymphocytes, and can serve as the basic groundwork for 
simulating multiple chemokine/chemoattraction axes involving more detailed cellular phenotypes. Further 
investigation of relevant chemokine relations between APC, RFC, and T cells would lead to a more mechanistic 
implementation of the model, which could then inform the design of future in vivo studies. The generalized 
gradient presented here can be replaced by specific chemokines observed in the microenvironment of tumor 
samples, or with chemokines that are known to be secreted by activated DC and/or stroma. In this way, mul-
tiple gradients can be modeled in concert. In addition, each chemokine gradient can be further developed 
beyond a two-dimensional Gaussian distribution taking into account extracellular matrix components that can 
bind to and slow the degradation of chemokines, better representing lymphocyte conduit systems observed 
in follicular structures in vivo28. So too can the responsiveness of activated cell populations be adjusted based 
on lymphocyte activation, and on negative feedback mediated by shingosine-1-phosphate receptor (S1P1) 
activity36–38.
Importantly, this model outlines the framework to simulate chemotactic movement of infiltrating populations 
in response to chemokine gradients. This alone inadequately represents the physiologic tumor microenviron-
ment, and in particular does not address immune cell polarity or immunosuppression. In addition to repre-
senting more defined subpopulations of immune cells, other soluble factors governing tumor-induced immune 
suppression will likely need to be added to fully capture the dynamic interplay of pro and anti-tumor elements. 
In particular, TFG-β, IL-10, and regulatory T cell populations are prevalent components of the tumor microen-
vironment known to suppress anti-tumor immunity39. Concurrently, the production of type I-polarizing factors 
such as IFN-γ and IL-12 can also be added as a counterbalance to these type II-polarizing factors40. Furthermore, 
it is now appreciated that the tumor as a system is heterogeneous, composed of numerous dominant and subdom-
inant clones with related but different genetic lesions and mutational loads46. This diversity results in compart-
mentalized spatial fields across the tumor bead, each with its own variation of environmental queues, grow rates, 
and immune involvement47. It is reasonable to expect that variations in the type and amount of soluble factors 
released can also vary across the tumor bed in accordance with clonal diversity. Such variations would directly 
impact the localization and function of infiltrating immune cells, and may be required to fully model the complex 
tumor physiology.
The addition of these factors in future models would result in a system whose outcome is not guaranteed, but 
would rather depend on the balance of pro and anti-tumor forces recruited or induced in the tumor microen-
vironment. The complexity such models will increase exponentially with the addition of individual chemokine 
gradients, further subdivision of inflammatory or suppressive cell types, the addition of polarizing soluble factors, 
and representation of clonal heterogeneity, necessitating the use of standardized datasets such as is presented 
here. The model introduced here, though simplified, clearly demonstrates the potential benefit of ELNs and sug-
gests that stromal/APC interaction is paramount for effector lymphocyte organization and response. Continued 
development of integrated ELNs formation models will greatly inform potential points of therapeutic interven-
tion, and generate novel hypotheses regarding anti-tumor immunity.
Cell Type Pan T CD4+T CD8+T B NK
CCL2 — — — — −/ + 
CCL3 — — — — −/+
CCL4 — — — — −/+
CCL5 — — — — −/+
CCL8 — — — — —
CCL18 — — — — —
CCL19 + + + −/+ ND
CCL21 + + + −/+ ND
CXCL9 −/+ −/+ −/+ — −/+
CXCL10 −/+ −/+ + — −/+
CXCL11 + — + — −/+
CXCL13 −/+ −/+ −/+ + —
Table 3. Chemotactic Index (CI) Summary for the 12-chemokine GES on Resting Lymphocytes. “−” No 
significant difference in CI at any chemokine dose. “−/+” p < 0.05 for at least one chemokine dose, but CI less 
than 5 for at least one chemokine dose. “+” p < 0.05 for at least one chemokine dose, and CI over 5 for at least 
one chemokine dose lg. ND Not determined.
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